In collaboration with MCPHS, Schrödinger is thrilled to introduce a two-year PharmD post-doctoral fellowship program focused on the clinical development of First-In-Human Phase I investigational agents as their expertise. This program offers a unique opportunity for fellows to gain broad and extensive experience in various functional areas in the development of phase I novel drugs, with emphasis on clinical science and clinical operations, but also including learning of various adult hematologic and solid tumors being studied, clinical pharmacology and pharmacodynamic, drug manufacturing, and regulatory affairs, to name a few. The fellowship will be located primarily in the Cambridge office, with occasional visits to the New York City office during the 2-year fellowship.
Program Objectives
Year 1: Foundation Building
Industry Overview: Develop a broad and comprehensive understanding of the pharmaceutical industry's key functional areas. Develop knowledge of Good Clinical Practice (cGCP) and International Council on Harmonization (ICH) guidelines.
Clinical Knowledge Expansion: Engage and hands-on experience and learnings of clinical trial management. Apply clinical, scientific knowledge to support and strategy in the design and conduct of early phase clinical studies in selected adult hematology and solid tumor.
Cross-Functional Collaboration: Work with cross-functional teams to gain insights into various industry sectors.
Year 2: Specialization and Leadership
Specialized Training: Focus on a particular functional area of interest within a therapeutic area of interest, such as clinical science, clinical operations, clinical pharmacology, regulatory affairs, etc.
Project Leadership: Take on leadership roles in special projects to develop management and decision-making skills. Training on strengthening presentation skills at internal meetings and at conferences.
Career Readiness: Build a robust professional network of various functional and clinical colleagues and build a solid skill set of knowledge and competencies for future employment opportunities.
To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews.
The MCPHS application portal will open up on Monday, October 7, 2024. Applicants must upload the following application materials to the online portal by Monday, November 4, 2024:
Letter of intent (addressed to the company specific program director/lead; found in each company brochure)
Curriculum vitae
Unofficial college transcript
Contact information for three references. References will receive an electronic recommendation form to complete separately.
Incomplete applications WILL NOT be reviewed. Interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
Recommendations
Three recommendation evaluation forms must be submitted no later than November 20, 2024via the online portal. This is NOT a letter of recommendation but an online form that the reference will need to complete.
Application Review and Interview Timeline
Following a review of submitted applications, pre-screens and preliminary interviews will begin in October. Additional interviews, including final rounds will take place in December during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore, candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.
ASHP Midyear & Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in New Orleans, LA. Attendance is strongly encouraged, but not required. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Top candidates may be invited for interviews at the sponsoring company’s location.
AIFA First Offer Date
The choice of a Post-Doctoral Fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for Fellowships no earlier than December 16, 2024. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship. We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date.
We see this respect for candidate choice as a common aspect of each of our Program's cultures. We hope that other academic and non-academic Fellowship Programs will respect this timeline.
Onboarding
Final candidates will be required to go through additional screening / onboarding as required by MCPHS.
Eligibility
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis.
Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
Schrödinger is a leader in scientific drug design and innovation, dedicated to advancing human health through the revolutionary discovery of therapeutics and materials.
With over 30 years of commitment to Research & Development, we are well-equipped to support educational collaborations, including our new partnership with MCPHS.MCPHS/Schrodinger.